ciprofol + butorphanol

Ciprofol + butorphanol is a drug combination being investigated for its efficacy and safety in providing anesthesia and analgesia during surgical procedures, such as breast tumor surgery. Ciprofol (HSK3486) is a novel intravenous anesthetic agent that acts as a potent Gamma-Aminobutyric Acid type A (GABA_A) receptor agonist, designed to offer a similar clinical profile to propofol but with higher potency and potentially fewer side effects like injection pain. Butorphanol is a mixed opioid agonist-antagonist, primarily acting as an agonist at the kappa-opioid receptor and a partial agonist or antagonist at the mu-opioid receptor, providing significant analgesic effects while reducing the risk of respiratory depression compared to pure mu-agonists. The combination is typically used to achieve balanced anesthesia, where ciprofol induces and maintains sedation/unconsciousness and butorphanol provides perioperative pain relief.

Other names

HSK3486 + butorphanol